SABR in oligometastatic breast cancer: Current status and future directions-Reference-Cited by-同舟云学术

SABR in oligometastatic breast cancer: Current status and future directions

Published:2021-12 Issue: Volume:60 Page:223-229
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Stewart Rachel^ORCID,White Michelle,Tan Jennifer,Siva Shankar,Karroum Lama,David Steven

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference64 articles.

1. Improved survival in metastatic breast cancer 1985-2016;Sundquist;Breast,2017

2. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial;Palma,2019

3. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial;Trovo;Radiother Oncol,2018

4. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study;Milano;Int J Radiat Oncol Biol Phys,2012

5. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer;Hammond;J Clin Oncol,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of ctDNA MRD precision medicine surveillance after definitive treatment of early-stage, high-risk breast cancer in a radiation oncology practice: A case series;Current Problems in Cancer: Case Reports;2024-06

2. Survival analysis of palliative radiotherapy in patients with HER-2+ metastatic breast cancer;Frontiers in Endocrinology;2024-01-08

3. ¿Se puede rescatar con irradiación la paciente con cáncer de mama oligometástasica?;Revista de Senología y Patología Mamaria;2023-10

4. Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy;npj Precision Oncology;2023-01-24

5. Ten-year experience of bone SBRT in breast cancer: analysis of predictive factors of effectiveness;Clinical and Translational Oncology;2023-01-16